reports
First Merchants Corporation Announces Changed Ex-Dividend Date for Pre...
First Merchants Corporation Announces Changed Ex-Dividend Date for Previously Announced Dividend MUNCIE, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (Nasdaq: FRME) has amended the ex-dividend date for its recently declared cash dividend of $0.36 from June 5, 2025, to June 6, 2025. The payment date for the quarterly dividend will remain as June 20, 2025, as previously announced on May 16, 2025. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service ban...
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference...
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
- Jonathan Moreland
CMI CUMMINS INC.
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
OEC ORION ENGINEERED CARBONS SA
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
BRKR BRUKER CORPORATION
ASYS AMTECH SYSTEMS INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
GCBC GREENE COUNTY BANCORP INC.
WINA WINMARK CORP.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
LILA INC.
COLD LIBERTY LATIN AMERICA A
EAF AMERICOLD REALTY TRUST
ULBI GRAFTECH INTERNATIONAL
MIDD ULTRALIFE
ENR THE MIDDLEBY CORPORATION
RPAY EDGEWELL PERSONAL CARE COMPANY
PRG REPAY HOLDINGS (A)
LESL PROG HOLDINGS
GRNT INC.
ALKT LESLIES
CVRX GRANIT SKOPKE
MINM ALKAMI TECHNOLOGY
MYO INC.
FLNC CVRX
DCGO INC.
STGW MINIM
OGN INC.
PFHC MYOMO
RXO_w FLUENCE ENERGY INC
OABI DOCGO INC
WEST STAGWELL INC
SRPT ORGANON & CO
FTK PROFRAC HLDG CORP
TXO RXO INC
AESI OMNIAB INC
FINS WESTROCK COFFEE COMPANY LLC
SAREPTA THERAPEUTICS
INC.
FLOTEK INDUSTRIES INC.
MORNINGSTAR PARTNERS
L.P.
ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
- Jonathan Moreland
UNH UNITEDHEALTH GROUP INCORPORATED
PEB PEBBLEBROOK HOTEL TRUST
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
FISV FISERV INC.
ASYS AMTECH SYSTEMS INC.
HTLD HEARTLAND EXPRESS INC.
EB EVENTBRITE
MIDD THE MIDDLEBY CORPORATION
RPAY REPAY HOLDINGS (A)
DLHC DALEIGH HOLDINGS CORP
GRNT GRANIT SKOPKE
ALKT ALKAMI TECHNOLOGY
PFHC INC.
RXO_w PROFRAC HLDG CORP
WEST RXO INC
FTK WESTROCK COFFEE COMPANY LLC
FG FLOTEK INDUSTRIES INC.
AESI F AND G ANNUITIES AND LIFE
FINS INC.
LBTYK ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
LIBERTY GLOBAL LTD.
First Merchants Corporation Announces Cash Dividend
First Merchants Corporation Announces Cash Dividend MUNCIE, Ind., May 16, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (NASDAQ: FRME) declared a cash dividend on May 16, 2025 of $0.36 per share. The dividend is payable on June 20, 2025, to common shareholders of record as of June 6, 2025. For purposes of broker trading, the ex-date of the cash dividend is June 5, 2025. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank als...
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceuti...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results...
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individual...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences C...
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, Ma...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections U...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a p...
First Merchants Corporation Announces First Quarter 2025 Earnings Per ...
First Merchants Corporation Announces First Quarter 2025 Earnings Per Share MUNCIE, Ind., April 24, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (NASDAQ - FRME) First Quarter 2025 Highlights: Net income available to common stockholders was $54.9 million and diluted earnings per common share totaled $0.94 compared to adjusted net income and diluted earnings per common share1 of $50.1 million and $0.85 in the first quarter of 2024. Adjusted net income and diluted earnings per common share1 in the fourth quarter of 2024 were $58.1 million and $1.00, respectively.Robust capital ...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndr...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug ...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Sc...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan...
First Merchants Corporation Announces Cash Dividend on its Preferred S...
First Merchants Corporation Announces Cash Dividend on its Preferred Stock MUNCIE, Ind., April 14, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation has declared a quarterly cash dividend of $46.88 per share on its 7.50% Non-Cumulative Perpetual Preferred Stock Series A, represented by depositary shares (NASDAQ: FRMEP) each representing a 1/100th interest in a share of the Series A preferred stock. Holders of depositary shares will receive $0.4688 per depositary share. The dividend will be payable on May 15, 2025, to stockholders of record on April 30, 2025. About First Merchants Corp...
Beyond Air Publishes Article in Annals of the American Thoracic Societ...
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent In...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Di...
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company...
First Merchants Corporation to Report First Quarter 2025 Financial Res...
First Merchants Corporation to Report First Quarter 2025 Financial Results, Host Conference Call and Webcast MUNCIE, Ind., April 03, 2025 (GLOBE NEWSWIRE) -- First Merchants Corporation (Nasdaq:FRME) will report first quarter 2025 financial results on April 24, 2025. The Corporation will host a first quarter 2025 earnings conference call and webcast at 11:30 a.m. (ET) on Thursday, April 24, 2025. To access via phone, participants will need to register using the following link where they will be provided a phone number and access code: () In order to view the webcast and presentation sli...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of ...
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demo...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, ...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virt...
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference, Apri...
Beyond Air Announces Vanderbilt University Medical Center as First Lum...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.